NUDT15 Gene Polymorphism Related to Mercaptopurine Intolerance in Taiwan Chinese Children with Acute Lymphoblastic Leukemia

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2015 Oct 28

PMID 26503813

Citations 50

Authors

D-C Liang

C-P Yang

H-C Liu

T-H Jaing

S-H Chen

I-J Hung

T-C Yeh

T-H Lin

C-L Lai

C-Y Lai

L-Y Shih

Affiliations

Soon will be listed here.

Abstract

A recent study identified a variant of the NUDT15 gene (rs116855232 C>T) associated with intolerance to thiopurine in Korean patients with Crohn's disease. This study prompted us to substantiate the finding in a Taiwanese population. Four hundred and four children with acute lymphoblastic leukemia (ALL), and 100 adults with chronic immune thrombocytopenic purpura or localized lymphoma having normal bone marrow were examined. Two candidate gene approaches, pyrosequencing for NUDT15 and TaqMan assay for thiopurine methyltransferase (TPMT) genotyping (rs1142345 A>G), were performed. We showed a risk allele frequency of NUDT15 of 11.6% in children with ALL and 15.5% in adults. By contrast, the risk allele frequency of TPMT was only 1.6% in children with ALL and 0.5% in adults. The high frequency of risk variant for NUDT15, but not the very low frequency of risk variant for TPMT, was closely associated with the intolerance to mercaptopurine in children with ALL in Taiwan, contrast to that of European descent. In regard to NUDT15 polymorphism, the maximal tolerable daily doses of mercaptopurine in homozygotes, heterozygotes and wild-type groups were 9.4 mg m, 30.7 mg m and 44.1 mg m, respectively. The outcomes did not differ significantly among the different genotypes.

Citing Articles

Polymorphism and Its Association With Mercaptopurine Hematotoxicity in Acute Lymphoblastic Leukemia in Indonesian Children.

Rosdiana D, Saputri D, Louisa M, Setiabudy R In Vivo. 2024; 38(4):2041-2048.

PMID: 38936894 PMC: 11215610. DOI: 10.21873/invivo.13662.

Association of gene polymorphism with adverse reaction, treatment efficacy, and dose of 6-mercaptopurine in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.

Du S, Huang X, He X, Mao M, Chen M, Zhang R Haematologica. 2023; 109(4):1053-1068.

PMID: 37794799 PMC: 10985454. DOI: 10.3324/haematol.2023.282761.

Comparative assessment of anti-cancer drugs against NUDT15 variants to prevent leucopenia side effect in leukemia patients.

V J, M S, Alsharif K, Halawani I, Ahmed S, Patil S J Genet Eng Biotechnol. 2023; 21(1):82.

PMID: 37556043 PMC: 10412517. DOI: 10.1186/s43141-023-00538-1.

Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.

Chikondowa P, Munkombwe D, Chikwambi Z, Kuona P, Masimirembwa C Pharmacogenomics. 2023; 24(8):449-457.

PMID: 37248698 PMC: 10463210. DOI: 10.2217/pgs-2023-0026.

Nudix Hydroxylase 15 Mutations Strongly Predict Thiopurine-Induced Leukopenia Across Different Asian Ethnicities: Implications for Screening in a Diverse Population.

Khoo X, Wong S, Wan Ibrahim N, Ng R, Chew K, Lee W Front Med (Lausanne). 2022; 9:880937.

PMID: 35991642 PMC: 9388767. DOI: 10.3389/fmed.2022.880937.

References

Stet E, De Abreu R, Bokkerink J, Lambooy L, Keizer-Garritsen J, Trijbels F . Reversal of methylmercaptopurine ribonucleoside cytotoxicity by purine ribonucleosides and adenine. Biochem Pharmacol. 1995; 49(1):49-56. DOI: 10.1016/0006-2952(94)00387-2. View

Krynetski E, Krynetskaia N, Yanishevski Y, Evans W . Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol Pharmacol. 1995; 47(6):1141-7. View

Kumagai K, Hiyama K, Ishioka S, Sato H, Yamanishi Y, McLeod H . Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics. 2001; 11(3):275-8. DOI: 10.1097/00008571-200104000-00012. View

Chang J, Lee L, Chen C, Shih M, Wu M, Tsai F . Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics. 2002; 12(3):191-5. DOI: 10.1097/00008571-200204000-00003. View

Relling M, Hancock M, Rivera G, Sandlund J, Ribeiro R, Krynetski E . Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999; 91(23):2001-8. DOI: 10.1093/jnci/91.23.2001. View

Pui C, Carroll W, Meshinchi S, Arceci R . Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29(5):551-65. PMC: 3071256. DOI: 10.1200/JCO.2010.30.7405. View

Liang D, Yang C, Lin D, Hung I, Lin K, Chen J . Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2009; 24(2):397-405. DOI: 10.1038/leu.2009.248. View

Liu H, Yeh T, Hou J, Chen K, Huang T, Chang C . Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(17):1825-9. DOI: 10.1200/JCO.2013.54.5020. View

Relling M, Hancock M, Boyett J, Pui C, Evans W . Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999; 93(9):2817-23. View

10.

Yang S, Hong M, Baek J, Choi H, Zhao W, Jung Y . A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014; 46(9):1017-20. PMC: 4999337. DOI: 10.1038/ng.3060. View

11.

Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C . Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014; 15(8):809-18. DOI: 10.1016/S1470-2045(14)70243-8. View

12.

Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H . Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2009; 24(2):265-84. DOI: 10.1038/leu.2009.257. View

13.

Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T . Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol. 1995; 13(2):345-51. DOI: 10.1200/JCO.1995.13.2.345. View

14.

Tinel M, Berson A, Pessayre D, Letteron P, Cattoni M, Horsmans Y . Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol. 1991; 32(6):729-34. PMC: 1368554. View

15.

Yang J, Landier W, Yang W, Liu C, Hageman L, Cheng C . Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015; 33(11):1235-42. PMC: 4375304. DOI: 10.1200/JCO.2014.59.4671. View

16.

Lennard L, Lilleyman J, van Loon J, Weinshilboum R . Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990; 336(8709):225-9. DOI: 10.1016/0140-6736(90)91745-v. View

17.

Hunger S, Lu X, Devidas M, Camitta B, Gaynon P, Winick N . Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012; 30(14):1663-9. PMC: 3383113. DOI: 10.1200/JCO.2011.37.8018. View

18.

Klemetsdal B, Tollefsen E, Loennechen T, Johnsen K, Utsi E, Gisholt K . Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther. 1992; 51(1):24-31. DOI: 10.1038/clpt.1992.4. View

19.

Takagi Y, Setoyama D, Ito R, Kamiya H, Yamagata Y, Sekiguchi M . Human MTH3 (NUDT18) protein hydrolyzes oxidized forms of guanosine and deoxyguanosine diphosphates: comparison with MTH1 and MTH2. J Biol Chem. 2012; 287(25):21541-9. PMC: 3375575. DOI: 10.1074/jbc.M112.363010. View

20.

Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G . 'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia. 2010; 24(2):253-4. DOI: 10.1038/leu.2009.276. View